Association of Epicardial Fat Volume With Increased Risk of Obstructive Coronary Artery Disease in Chinese Patients With Suspected Coronary Artery Disease

Wenji Yu, MD; Bao Liu, MD; Feifei Zhang, MD; Jianfeng Wang, MD; Xiaoliang Shao, MD; Xiaoyu Yang, MD; Yunmei Shi, MD; Bing Wang, MD; Yiduo Xu, MD; Yuetao Wang, MD

BACKGROUND: Epicardial adipose tissue may be associated with the pathogenesis of coronary artery disease (CAD), but its effect on obstructive CAD risk is uncertain. Therefore, we aimed to examine the relationship between epicardial adipose tissue and obstructive CAD in Chinese patients with suspected CAD.

METHODS AND RESULTS: The present study enrolled 194 consecutive inpatients with suspected CAD who underwent both noncontrast computed tomography and coronary angiography. We measured epicardial fat volume (EFV) and evaluated its association with obstructive CAD, which was defined as coronary stenosis severity ≥70%. Overall, 44.3% patients had obstructive CAD and tended to have higher EFV. Age, body mass index, triglycerides, incidence of hypertension, and hyperlipidemia were higher across tertiles of EFV (P for trend <0.05). In univariate regression analysis, a per-SD increase in EFV was independently associated with obstructive CAD (odds ratio [OR], 2.31; 95% CI, 1.61–3.32; P<0.001). Consistent with these findings, EFV was still significantly related to obstructive CAD as continuous variable after adjustment for all traditional risk factors and coronary artery calcium (OR per SD, 2.82; 95% CI, 1.68–4.74; P<0.001). Generalized additive model indicated that EFV was linearly associated with risk of obstructive CAD. E-value analysis suggested robustness to unmeasured confounding.

CONCLUSIONS: Our results suggested that in Chinese patients with suspected CAD, EFV was significantly and positively associated with the risk of obstructive CAD, independent of traditional risk factors and coronary artery calcium.

Key Words: coronary artery calcium ■ epicardial fat volume ■ noncontrast computed tomography ■ obstructive coronary artery disease
CAD has been confirmed, the patient’s event risk will be determined, and it has a major influence on subsequent therapeutic decisions. Revascularization was recommended for patients with obstructive CAD to effectively eliminate myocardial ischemia and angina symptoms. Therefore, it is interesting to identify reliable markers of obstructive CAD early to reassess preprocedural risk.

Epicardial adipose tissue (EAT), a metabolic active adipose tissue confined within pericardium, is usually quantified by epicardial fat volume (EFV) from noncontrast computed tomography (CT). Because of the close anatomical association and lack of fibrous fascia separating EAT from myocardium and coronary arteries, inflammatory cytokines secreted by EAT interact with coronary arteries and myocardium through direct paracrine effect and endocrine effect. In addition, there is growing evidence showing that EFV could alter vascular homeostasis and promote endothelial dysfunction. It is also reported that statin therapy and intense lifestyle modification could reduce EAT accumulation and affect inflammatory profile simultaneously, which made EAT a promising marker for primary prevention of obstructive CAD.

Previous studies have demonstrated that EFV is clinically associated with atherosclerosis and presence and severity of CAD, along with an increased incidence of cardiovascular adverse events. Recently, a large Chinese population-based study demonstrated that EFV improved prediction of CAD above traditional risk factors and coronary artery calcium score (CACS). Besides, Iwasaki et al found that EFV increased only if CAD with luminal stenosis was ≥70%. Differently, a multicenter study failed to find the associations between EFV and CAD. Besides, ethnic differences in EFV have been highlighted previously, and race might be a significant influencing factor when evaluating the relationship between EFV and cardiovascular risk. Most of clinical studies were performed in western population and focused on the relationship between EFV and CAD. The association between EFV and obstructive CAD was only investigated in a limited number of studies, which was still unclear in Chinese population.

Thus, the purpose of the present study was to explore the relationship between EFV and obstructive CAD in Chinese patients with suspected CAD.

METHODS

The data that support the findings of this study are available from the corresponding author on reasonable request.

Study Population

The present study enrolled 194 consecutive inpatients with suspected CAD who underwent noncontrast chest CT and CAG between March 2018 and October 2019 at the Third Affiliated Hospital of Soochow University. CAG was produced within 3 months of noncontrast chest CT in all patients. Patients enrolled had intermediate pretest probability for CAD (pretest probability of CAD, 59.23±20.92%). Traditional CAD risk factors were recorded, including body mass index (BMI), hypertension, hyperlipidemia, diabetes mellitus (DM), active smoking, and symptoms (including angina, dyspnea, atypical chest pain, and dyspnea with angina or atypical chest pain). Height and weight were measured to ascertain BMI. Hypertension was defined as systolic blood pressure ≥140 mm Hg, diastolic blood pressure ≥90 mm Hg, or taking antihypertensive medications. Hyperlipidemia, diabetes mellitus (DM), active smoking, and symptoms (including angina, dyspnea, atypical chest pain, and dyspnea with angina or atypical chest pain). Height and weight were measured to ascertain BMI. Hypertension was defined as systolic blood pressure ≥140 mm Hg, diastolic blood pressure ≥90 mm Hg, or taking antihypertensive medications. Hyperlipidemia was defined as a history of hyperlipidemia, total cholesterol >5.2 mmol/L, low-density lipoprotein cholesterol >3.36 mmol/L, or use of lipid-lowering medication. DM was defined by random plasma glucose ≥8.0 mmol/L or self-reported history of DM. Active smoking was defined as smoking within past 6 months. Triglycerides, total cholesterol, low-density lipoproteins, and high-density lipoproteins (HDLs) were extracted from patients’ records.
The exclusion criteria were as follows: (a) subjects with acute coronary syndrome, (b) subjects with prior percutaneous coronary intervention or coronary artery bypass grafting, (c) subjects with severe arrhythmia, (d) aged <18 years, and (e) pregnancy. Figure 1 shows the flowchart of population selection. The Medical Ethics Committee of our hospital approved this study protocol. The data are anonymous, and the requirement for informed consent was waived because of the observational nature of the study.17

Measurement of EFV and CACS
A noncontrast CT chest scan was performed (period, 60%-80% RR; tube voltage, 130 kV; tube current, 100 mA; thickness, 3 mm) to acquire CACS and EFV using retrospective electrocardiography-gated technology (Symbia T16; Siemens Medical Systems, Erlangen, Germany). Each scan extended from the plane underneath the tracheal carina to the place 1 to 2 cm below heart diaphragmatic surface, almost 20 cm. EAT was identified as any adipose tissue observed within the pericardial sac with fat voxels (attenuation values between −30 and −190 hounsfield unit [HU]).18 The specific method is as follows: First, the upper slice limit, defined by bifurcation of the pulmonary trunk, and the lower slice limit, marked as the last slice containing any portion of the heart, were defined. Then, the reader manually traced the pericardial contour. EFV was calculated by the sum of cross-sectional areas of fat multiplied by slice thickness.19 The whole process was performed by the software (Syngo Volume; Siemens Medical Solutions). The interobserver reproducibility of EFV was tested among 2 observers in 15 patients (intraclass correlation coefficient, 0.908; 95% CI, 0.750–0.968; P<0.001). Coronary artery calcium (CAC) was defined as a dense area in the coronary artery over the threshold of 130 HU. CACS was defined as the sum of calcification score of each coronary artery by using Agatston automatic analysis software.20

Coronary Angiography
CAG was completed by standard techniques via a femoral or radial approach. All coronary angiograms were visually evaluated by an experienced cardiologist.

---

**Figure 1.** The flowchart of population selection.
CAD indicates coronary artery disease; CAG, coronary angiography; CT, computed tomography; and PCI, percutaneous coronary intervention.
They were blinded of patients’ clinical information. Obstructive CAD was defined as ≥70% narrowing of the internal diameter of the left anterior descending coronary artery, left circumflex coronary artery, right coronary artery, or their major branches, or ≥50% narrowing of the left main coronary artery.21

**Radiation Exposure**
The dose for a noncontrast CT scan to assess CACS and EFV was 1 to 2 mSv.

**Statistical Analysis**
Continuous variables are expressed as mean±SD when normally distributed and median (25th–75th percentile) when nonnormally distributed. Normality was assessed for each variable by the Kolmogorov-Smirnov test. We compared baseline characteristics between patients with or without obstructive CAD. Mann-Whitney U test, independent-sample t-test, and χ² test were performed, as appropriate. The influence of factors related to tertiles of EFV was evaluated by trend test. Multivariable logistic regression models were produced to assess the association between EFV and obstructive CAD; 4 models were generated: (1) a univariable model with EFV as a predictor; (2) multivariable model 1, adjusted for age and sex; (3) multivariable model 2 (confounder model): we assessed the confounding effect of covariates by examining the association of EFV with obstructive CAD before and after adding the covariate. If the scale of the β coefficient changed by >10%, we concluded that the covariate was a confounder. Besides, any variable that was significantly different between obstructive CAD and nonobstructive CAD group (P<0.10) was also retained as confounder. (4) Multivariable model 3 was constructed on the basis of our team’s interpretation of a broad review of the literature, and adjusted for age, sex, BMI, hypertension, DM, hyperlipidemia, active smoking, and CAC. From the models, we present odds ratios (ORs) and 95% CIs. Collinearity between independent variables was assessed, and only variables with correlation coefficients R<0.25 or variance inflation factors <5 were contained. General additive model and cubic spline smoothing technique were performed to evaluate the association between EFV and the incidence of obstructive CAD. We explored the potential for unmeasured confounding by calculating E values.22 The E value quantifies the required magnitude of an unmeasured confounder that could negate the observed association between EFV and obstructive CAD. Interaction and stratified analyses were conducted according to sex. All tests were performed 2 sided with R3.4.3 (http://www.R-project.org; software packages: glmnet, pROC, rms, and dca. R) and Prism 7 (GraphPad Software, San Diego, CA). P<0.05 indicated statistical significance.

**RESULTS**

**Patient Characteristics**
Baseline characteristics of all patients are shown in Table 1, and 86 (44.3%) patients had obstructive CAD. Overall, the mean age was 61.38±9.64 years, 136 (70.1%) were men, and mean BMI was 24.86±2.94 kg/m². Mean EFV was 119.47±36.56 cm³ (range, 37.30–246.49 cm³). Compared with patients without obstructive CAD, patients with obstructive CAD tend to have higher value of EFV (133.87±36.59 cm³ versus 108.00±32.37 cm³; P<0.001), as well as a higher proportion of DM and CAC and lower value of HDL. Table 2 demonstrated the influence factors of EFV. Age, BMI, triglycerides, and incidence of hypertension and hyperlipidemia were higher across tertiles of EFV (P for trend <0.05).

**Univariable Logistic Regression Analysis Between EFV and Obstructive CAD**
The relationship between EFV and obstructive CAD was presented in Table 3. According to the results of unadjusted logistic regression analysis, a per-SD increase in EFV was independently associated with obstructive CAD (OR, 2.31; 95% CI, 1.61–3.32; P<0.001), and the OR for obstructive CAD was 5.59 (95% CI, 2.62–11.95; P<0.001) in patients with EFV of top tertile compared with those in the bottom tertile.

**Multivariable Logistic Regression Analysis Between EFV and Obstructive CAD**
The multivariable logistic regression analysis also demonstrated a significant association between EFV and obstructive CAD. In multivariable-adjusted model 1 (adjusted for age and sex), the OR for obstructive CAD progressively increased across tertiles of EFV (P for trend <0.001), and for a per-SD increase in EFV, the OR was 2.24 (95% CI, 1.55–3.23; P<0.001). Adjustment for confounders in multivariable-adjusted model 2 (age, sex, BMI, hypertension, DM, HDL, and CAC) also did not significantly alter the results. After adjustment for all traditional risk factors and CAC in multivariable-adjusted model 3 with the bottom tertile (tertile 1) as reference, the OR was 3.34 for middle tertile (tertile 2) (95% CI, 1.37–8.15; P=0.008) and 9.28 for top tertile (tertile 3) (95% CI, 3.14–27.41; P<0.001). Consistent with these findings, multivariate analysis demonstrated that EFV as continuous variable was still significantly related to obstructive CAD (OR for per SD, 2.82; 95% CI, 1.68–4.74; P<0.001). Figure 2 shows the forest plot presenting the multivariable-adjusted ORs from multivariable-adjusted model 3. When stratifying the population by sex, the OR between EFV (per SD) and obstructive CAD was similar after adjustment for
Yu et al. Epicardial Fat Volume and Coronary Artery Disease

Traditional risk factors and CAC (men: OR, 2.52 [95% CI, 1.44–4.38]; women: OR, 4.17 [95% CI, 1.54–11.33]; P interaction=0.34).

Generalized additive model (Figure 3) was performed to visually assess association between EFV and risk of obstructive CAD after adjusting for age, sex, BMI, presence of hypertension, hyperlipidemia, DM, active smoking, and CAC. It turned out that EFV tended to be linearly associated with obstructive CAD.

We generated an E value to assess the sensitivity to unmeasured confounding. The primary findings were

| Table 1. Characteristics of Studied Patients |
|--------------------------------------------|
| Characteristics                               | All Patients (N=194) | Obstructive CAD (N=86) | No Obstructive CAD (N=108) | P Value |
| Age, y                                      | 61.38±9.64          | 62.84±10.14            | 60.22±9.01                 | 0.02*   |
| Men, n (%)                                  | 138 (70.1)          | 66 (76.7)              | 70 (64.8)                  | 0.07    |
| BMI, kg/m²                                  | 24.86±2.94          | 25.09±2.85             | 24.68±3.01                 | 0.27    |
| Active smoking, n (%)                       | 37 (38.1)           | 37 (43.0)              | 37 (34.3)                  | 0.21    |
| Hypertension, n (%)                         | 139 (71.2)          | 67 (77.9)              | 72 (66.7)                  | 0.08    |
| Diabetes mellitus, n (%)                   | 59 (30.1)           | 34 (39.5)              | 25 (23.1)                  | 0.014*  |
| Hyperlipidemia, n (%)                       | 61 (31.4)           | 28 (32.6)              | 33 (54.1)                  | 0.75    |
| TC, mmol/L                                  | 3.90±0.91           | 3.82±0.83              | 3.96±0.95                  | 0.24    |
| Triglycerides, mmol/L                      | 1.78±0.95           | 1.75±0.97              | 1.80±0.93                  | 0.70    |
| HDL, mmol/L                                 | 1.06±0.26           | 1.00±0.23              | 1.11±0.27                  | 0.01*   |
| LDL, mmol/L                                 | 2.02±0.69           | 2.02±0.64              | 2.03±0.73                  | 0.88    |
| Symptom, n (%)                              | 128 (66.0)          | 58 (67.4)              | 70 (64.8)                  | 0.70    |
| CAC prevalence, n (%)                       | 105 (54.1)          | 64 (74.4)              | 41 (38.0)                  | <0.001* |
| EFV, cm³                                    | 119.47±36.56        | 133.87±36.59           | 108.00±32.37               | <0.001* |

Data are given as mean±SD, unless otherwise indicated. Symptom includes angina, dyspnea, atypical chest pain, and dyspnea with angina or atypical chest pain. BMI indicates body mass index; CAC, coronary artery calcium; CAD, coronary artery disease; EFV, epicardial fat volume; HDL, high-density lipoprotein; LDL, low-density lipoprotein; and TC, total cholesterol.

*P<0.05.

| Table 2. Baseline Characteristics Stratified by Tertiles of EFV |
|---------------------------------------------------------------|
| Characteristics                                               | Bottom Tertile | Middle Tertile | Top Tertile | P Value for Trend |
| EFV, minimum–maximum, cm³                                      | 37.30–107.36   | 107.36–128.49 | 128.49–246.49 | 0.003* |
| EFV, mean (SD), cm³                                            | 83.34 (18.69)  | 117.06 (6.60) | 157.97 (38.31) | 0.003* |
| EFV, median (IQR), cm³                                         | 87.14 (30.85)  | 116.61 (11.23) | 147.2 (34.24) | 0.003* |
| Age, y                                                        | 58.22±9.87     | 62.25±8.80    | 63.69±9.49    | 0.003* |
| Men, n (%)                                                    | 45 (69.23)     | 44 (68.75)    | 47 (72.31)    | 0.70  |
| BMI, kg/m²                                                    | 23.17±2.70     | 24.76±2.31    | 26.64±2.73    | <0.001* |
| Symptom, n (%)                                                | 39 (60.00)     | 42 (65.62)    | 47 (72.31)    | 0.14  |
| Active smoking, n (%)                                         | 24 (36.92)     | 20 (31.25)    | 30 (48.15)    | 0.28  |
| Hypertension, n (%)                                           | 40 (61.54)     | 44 (68.75)    | 55 (84.62)    | 0.003* |
| Diabetes mellitus, n (%)                                      | 18 (27.69)     | 16 (25.00)    | 25 (38.46)    | 0.18  |
| Hyperlipidemia, n (%)                                         | 16 (24.62)     | 16 (25.00)    | 29 (44.62)    | 0.020* |
| TC, mmol/L                                                    | 3.98±0.87      | 3.78±0.85     | 3.93±0.98     | 0.42  |
| Triglycerides, mmol/L                                         | 1.62±0.99      | 1.71±0.76     | 2.01±1.04     | 0.044* |
| HDL, mmol/L                                                   | 1.11±0.31      | 1.06±0.22     | 1.03±0.23     | 0.19  |
| LDL, mmol/L                                                   | 2.10±0.77      | 1.93±0.57     | 2.04±0.71     | 0.37  |
| CAC prevalence, n (%)                                         | 31 (47.69)     | 34 (53.12)    | 40 (61.54)    | 0.11  |
| Obstructive CAD, n (%)                                        | 16 (24.6)      | 28 (43.8)     | 42 (64.6)     | <0.001* |

Data are given as mean±SD, unless otherwise indicated. Symptom includes angina, dyspnea, atypical chest pain, and dyspnea with angina or atypical chest pain. BMI indicates body mass index; CAC, coronary artery calcium; CAD, coronary artery disease; EFV, epicardial fat volume; HDL, high-density lipoprotein; IQR, interquartile range; LDL, low-density lipoprotein; and TC, total cholesterol.

*P for trend <0.05.
robust. For unmeasured confounding to change our results that EFV was significantly related to obstructive CAD would be unlikely (E value, 2.75).

**DISCUSSION**

The main findings of the study were as follows. (1) Compared with patients without obstructive CAD, individuals with obstructive CAD had a higher value of EFV, as well as a higher proportion of DM and CAC, and lower value of HDL. (2) Age, BMI, triglycerides, and prevalence of hypertension and hyperlipidemia increased with tertiles of EFV. (3) In multivariable logistic regression analysis, EFV was significantly and positively associated with obstructive CAD, independent of traditional risk factors and CAC. Generalized additive model indicated that EFV was linearly associated with risk of obstructive CAD.

| Variable                  | Crude Model                          | Multivariable-Adjusted Model 1 | Multivariable-Adjusted Model 2 | Multivariable-Adjusted Model 3 |
|---------------------------|--------------------------------------|--------------------------------|--------------------------------|--------------------------------|
| EFV (continuous) per SD   | 2.31 (1.61–3.32) <0.001              | 2.24 (1.55–3.23) <0.001        | 2.73 (1.63–4.57) <0.001        | 2.82 (1.68–4.74) <0.001        |
| Tertiles                  |                                      |                                |                                |                                |
| Bottom tertile (events/  | 1                                    | 1                              | 1                              | 1                              |
| N=16/65)                  |                                      |                                |                                |                                |
| Middle tertile (events/  | 2.38 (1.13–5.04) 0.02                | 2.26 (1.06–4.85) 0.04          | 3.23 (1.31–7.99) 0.011         | 3.34 (1.37–8.15) 0.008         |
| N=28/64)                  |                                      |                                |                                |                                |
| Top tertile (events/      | 5.59 (2.62–11.95) <0.001             | 5.15 (2.36–11.25) <0.001       | 8.84 (3.03–25.83) <0.001       | 9.28 (3.14–27.41) <0.001       |
| N=42/65)                  |                                      |                                |                                |                                |

Multivariable model 1 was adjusted for age and sex; multivariable model 2 (confounder model) was adjusted for age, sex, body mass index, hypertension, diabetes mellitus, high-density lipoprotein, and coronary artery calcium prevalence; and multivariable model 3 was adjusted for age, sex, body mass index, hypertension, diabetes mellitus, active smoking, hyperlipidemia, and coronary artery calcium prevalence. CAD indicates coronary artery disease; EFV, epicardial fat volume; and OR, odds ratio.

*For trend, P<0.001.

**Figure 2.** Forest plot presenting the multivariable-adjusted odds ratios (ORs) from multivariable-adjusted model 3. EFV indicates epicardial fat volume.
indicated different risk in different ethnic groups. Sun et al\(^7\) demonstrated that indigenous individuals had significantly higher EFV than nonindigenous individuals in Australia and supported the possibility that EAT may result in the greater burden of cardiovascular disease in indigenous populations. We are in agreement with those studies and extend the results in Chinese Han population. Because our results were obtained in a homogeneous population of Chinese Han, the findings cannot be extrapolated to other ethnic populations. Further studies are needed to demonstrate whether the results are generalizable to different ethnic populations. In addition, EAT can be modified to improve cardiovascular risk, which might provide a new method for primary prevention of CAD. Kim et al\(^25\) found that EAT was significantly reduced by aerobic exercise training, and the percentage change of EAT was twice higher than those of waist circumference and BMI. Colonetti et al\(^6\) indicated that no matter what type of exercise could significantly reduce EAT.

Our results indicated that EFV was significantly and positively associated with obstructive CAD, and after adjustment for traditional risk factors and CAC, the risk for obstructive CAD went up by 1.82 times for each SD increase in EFV. Different from BMI, EFV represents visceral adiposity rather than general obesity, and the quantitative determination of EFV may offer additional information on cardiovascular risk. Because obstructive CAD is highly related to myocardial ischemia and major adverse cardiovascular events and may benefit more from revascularization, this simple measurement of EFV may help select certain patients for high-dose statin therapy, intense lifestyle modification, and revascularization, if needed. There has been limited research considering the relationship between EFV and obstructive CAD based on western population. Sinha et al\(^26\) found that EAT thickness, measured by echocardiography, was significantly associated with obstructive CAD by CAG. Different from this study, we quantified EAT by CT, which is also proved to be a repeatable and robust method to evaluate adipose tissue accumulation because of high spatial resolution.\(^27\) Besides, Rajani et al\(^28\) also concluded that, in patients with noncalcified or partially calcified disease, EFV is significantly associated with coronary stenosis severity \(\geq 70\%), assessed by coronary CT angiography. In the present study, CAD was evaluated by CAG, which is considered as gold standard. In contrast, some studies came to opposite conclusion, and it is still unclear whether EAT could provide significant clinical value as an imaging biomarker of cardiovascular risk. The CORE320 (Coronary Artery Evaluation using 320-row Multidetector Computed Tomography Angiography and Myocardial Perfusion) Multicenter Study\(^13\) did not find association between EFV and O:\(^2\)

**Figure 3.** General additive model demonstrated the relationship between epicardial fate volume (EFV) and the risk of obstructive coronary artery disease (CAD) after adjusting for age, sex, body mass index, presence of hypertension, hyperlipidemia, diabetes mellitus, active smoking, and coronary artery calcium.

In the figure, the solid line indicates the estimated risk of obstructive CAD, and the dotted lines represent pointwise 95% CI.

EAT locates close to the coronary arteries, accounts for 15% to 20% of cardiac volume, and covers \(\sim 80\)% of cardiac surface. Its unique anatomical proximity to the myocardium and the coronary arteries led to the hypothesis that EAT played a pivotal role in the pathogenesis of CAD, but the exact pathophysiological mechanism was still unclear. It was speculated that EAT could secret many inflammatory cytokines, including interleukin-1B, interleukin-6, MCP (monocyte chemotactic protein), and tumor necrosis factor; then, these proinflammatory signals act toward atherogenesis through endocrine effect and direct paracrine effect.\(^5\) EFV was reported to be associated with vulnerable plaques, such as “soft” and “mixed” plaques, which could result in negative outcomes.\(^23\) Besides, oxidative stress, coronary blood flow impairment, and endothelial damage were also speculated to account for the association observed between EFV and CAD in some studies.\(^7\)

It was demonstrated in the present study that EFV was related to cardiovascular risk factors, such as age, BMI, hypertension, and hyperlipidemia, in Chinese patients with suspected CAD. Similarly, Jang et al\(^24\) showed significant association of EAT with fasting blood glucose, triglyceride, HDL, and blood pressure in healthy adults aged <60 years. We extended the results by confirming them in patients with suspected CAD. Besides, there are significant racial differences in EFV and its relationship with cardiovascular risk factors. Moharram et al\(^14\) concluded that EAT thickness was significantly associated with BMI in New Zealand European patients, but not in Māori/Pacific patients, which demonstrated that the same level of BMI...
The categorical threshold in this study was ≥50% diameter stenosis by CAG, which may not account for the presence of plaque instability. EFV can be routinely acquired by noncontrast CT used for CACS, avoiding the need for dedicated diagnostic testing, which enhanced its attraction for clinical application. Cardiovascular risk assessment depends on traditional risk factors and has a limited performance, and 20% coronary events were reported to appear in patients without traditional risk factors, so the search for innovative and reproducible cardiovascular risk marker, such as EFV, seems promising. El Khoudary et al demonstrated that oral conjugated equine estrogens may slow EAT accumulation in recently menopausal women. Because the risk of CAD could be lowered by interventions to decrease EFV, EFV may serve as a potential therapeutic target more than a cardiovascular risk factor. Last, EFV was identified as an independent predictor of CAD group. Further prospective studies are necessary to evaluate the potential significance of EFV for clinical management.

**Limitations**

There are several limitations of our study. First, considering the retrospectively cross-sectional design of our study, we could not infer causality. Second, because no event follow-up was done, our study cannot verify prognostic implications. Third, anthropometric measures, such as waist circumference, were not measured in the study. Instead, we investigated traditional risk factors, including BMI, which is also an indicator of high cardiovascular risk and widely accepted as a parameter reflecting systemic body fat in clinical studies. Besides, we used the E-value analysis to quantify the potential implications of unmeasured confounders and found that an unmeasured confounder will not change the direction of our results. Besides, we focused on the relationship between EAT volume and obstructive CAD (≥70% stenosis) in Chinese population. More subjects should be included to further investigate the association between EFV and CAD in nonobstructive CAD group. Last, EFV measurement is still a time-consuming procedure without standardization; automatic software needs to be designed to make EFV a clinically useful imaging biomarker.

**CONCLUSIONS**

In Chinese patients with suspected CAD, EFV was significantly and positively associated with risk of obstructive CAD, independent of traditional risk factors and CAC. Further studies are needed to identify longitudinal changes in EFV.

**ARTICLE INFORMATION**

Received June 16, 2020; accepted January 14, 2021.

**Disclosures**

None.

**REFERENCES**

1. Hu S, Gao R, Liu L, Zhu M, Wang W, Wang Y, Wu Z, Li H, Gu D, Yang Y, et al. Summary of the 2018 report on cardiovascular diseases in China. Chin Circ J. 2019;34:209–220. DOI: 10.3969/j.issn.1000-3614.2019.03.001.

2. Chin PA, Fearon WF, De Bruyne B, Oldroyd KG, Leesar MA, Ver Lee PN, Maccarthy PA, Van’t Veer M, Pilis NH. Angiographic versus functional severity of coronary artery stenoses in the FAME study fractional flow reserve versus angiography in multivessel evaluation. J Am Coll Cardiol. 2010;55:2816–2821. DOI: 10.1016/j.jacc.2009.11.096.

3. Neglia D, Liga R, Caselli C, Carpeggiani C, Lorenzoni V, Scari R, Lombardi M, Gaemperli O, Kaufmann PA, Scholte A, et al. Anatomical and functional coronary imaging to predict long-term outcome in patients with suspected coronary artery disease: the EVINCI-outcome study. Eur Heart J Cardiovasc Imaging. 2020;21:1273–1282. DOI: 10.1093/ehjci/jez248.

4. Zheng X, Curtis JP, Hu S, Wang Y, Yang Y, Masoudi FA, Spertus JA, Li X, Li J, Dharmarajan K, et al. Coronary catheterization and percutaneous coronary intervention in China: 10-year results from the China PEACE-retrospective CathPCI study. JAMA Intern Med. 2016;176:512–521. DOI: 10.1001/jamainternmed.2016.0166.

5. Knuuti J, Wijns W, Saraste A, Capodanno D, Barbato E, Funck-Brentano C, Prescott E, Storey RF, Deaton C, Cuisset T, et al. 2019 ESC guidelines for the diagnosis and management of chronic coronary syndromes: the task force for the diagnosis and management of chronic coronary syndromes of the European Society of Cardiology (ESC). Eur Heart J. 2019;41:407–477. DOI: 10.1093/eurheartj/ehz425.

6. Sacks HS, Fain JN. Human epicardial adipose tissue: a review. Am Heart J. 2007;153:907–917. DOI: 10.1016/j.ahj.2007.03.019.

7. Sade LE, Eroglu S, Bozbah H, Oz bicer S, Hayran M, Haberal A, M u derriso lu H. Relation between epicardial fat thickness and coronary flow reserve in women with chest pain and angiographically normal coronary arteries. Atherosclerosis. 2008;204:580–585. DOI: 10.1016/j.atherosclerosis.2008.09.038.

8. Colonetti T, Grande AJ, Amaral MC, Colonetti L, Ug gioni ML, da Rosa ML, Hernandez AV, Tse G, Liu T, Nerlekar N, et al. Effect of exercise on epicardial adipose tissue in adults: a systematic review and
meta-analyses. Heart Fail. Rev. 2020. May 16 [epub ahead of print]. DOI: 10.1007/s10741-020-00965-5.

9. Nixdorf M, Schmidt JG, Grönemeyer D, Seibel R, Slomiany U, Beck EM, Öffner A, Münkel S, Bauer M, Schrader S. Noncoronary measures enhance the predictive value of cardiac CT above traditional risk factors and CAC score in the general population. JACC Cardiovasc Imaging. 2018;9:1177–1185. DOI: 10.1016/j.jcmg.2015.12.024.

10. Nixdorf M, Schmidt JG, Grönemeyer D, Seibel R, Slomiany U, Beck EM, Öffner A, Münkel S, Bauer M, Schrader S. Noncoronary measures enhance the predictive value of cardiac CT above traditional risk factors and CAC score in the general population. JACC Cardiovasc Imaging. 2018;9:1177–1185. DOI: 10.1016/j.jcmg.2015.12.024.

11. Zhou J, Chen Y, Zhang Y, Wang H, Tan Y, Liu Y, Huang L, Zhang H, Ma Y, Cong H. Epicardial fat volume improves the prediction of obstructive coronary artery disease above traditional risk factors and coronary calcium score. Circ Cardiovasc Imaging. 2019;12:e008002. DOI: 10.1161/ CIRCIMAGING.118.008002.

12. Iwasaki K, Matsumoto T, Aono H, Furukawa H, Samukawa K. Relationship between epicardial fat measured by 64-multidetector computed tomography and coronary artery disease. Clin Cardiol. 2011;34:168–171. DOI: 10.1002/clc.20340.

13. Tanami Y, Jinzaki M, Kishi S, Matheson M, Vavere AL, Rochitte CE, Dewey M, Chen MY, Clouse ME, Cox C, et al. Lack of association between epicardial fat volume and extent of coronary artery calcification, severity of coronary artery disease, or presence of myocardial perfusion abnormalities in a diverse, symptomatic patient population: results from the CORE320 multicenter study. Circ Cardiovasc Imaging. 2015;8:e002676. DOI: 10.1161/CIRCIMAGING.114.002676.

14. Moharram MA, Aitken-Buck HM, Reijers R, Hout IV, Williams MJ, Jones PP, Whalley GA, Lamberts RR, Coffey S. Correlation between epicardial adipose tissue and body mass index in New Zealand ethnic populations. NZ Med J. 2020;133:22–32.

15. Salami SS, Tucciaroni M, Bess R, Kolluru A, Szpunar S, Lin M. Lack of association between epicardial fat volume and extent of coronary artery calcification, severity of coronary artery disease, or presence of myocardial perfusion abnormalities in a diverse, symptomatic patient population: results from the CORE320 multicenter study. Circ Cardiovasc Imaging. 2015;8:e002676. DOI: 10.1161/CIRCIMAGING.114.002676.

16. Sun DF, Kangaharan N, Costello B, Nicholls SJ, Emdin CA, Tse R, Gallagher C, Kaur A, Roberts-Thomson KC, Mahajan R, et al. Epicardial and subcutaneous adipose tissue in indigenous and non-indigenous individuals: implications for cardiometabolic diseases. Obes Res Clin Pract. 2020;14:39–102. DOI: 10.1016/j.orcp.2019.12.001.

17. Filion KB, Azoulay L, Platt RW, Dahl M, Dormuth CR, Clemens KK, Hu N, Paterson JM, Targowik L, Turin TG, et al. A multicenter observational study of incretin-based drugs and heart failure. N Engl J Med. 2016;374:1145–1154. DOI: 10.1056/NEJMoa1506115.

18. Huang G, Wang D, Zeb I, Budoff MJ, Harman SM, Miller V, Brinton EA, El Khoudary SR, Manson JE, Sowers MR, et al. Intra-thoracic fat, cardiometabolic risk factors, and subclinical cardiovascular disease in healthy, recently menopausal women screened for the Kronos Early Estrogen Prevention Study (KEEPS). Atherosclerosis. 2012;222:199–205. DOI: 10.1016/j.atherosclerosis.2011.12.004.

19. Bettencourt N, Toschke AM, Leite D, Rocha J, Carvalho M, Sampaio F, Xará S, Leite-Moreira A, Nagel E, Gama V. Epicardial adipose tissue is an independent predictor of coronary atherosclerotic burden. Int J Cardiol. 2012;158:26–32. DOI: 10.1016/j.ijcard.2010.12.085.

20. Mahaisavariya R, Detrano R, Kang X, Garner D, Vo A, Georgiou D, Molloi S, Brundage BH. Quantitation of in vitro coronary artery calcium using ultrafast computed tomography. Catheter Cardiovasc Diagn. 1994;32:387–393. DOI: 10.1002/ccd.1803204241.

21. Betancur J, Commandeur F, Motlagh M, Sharir T, Einstein AJ, Bokhari S, Fish MB, Ruddy TD, Kaufmann P, Sinunas AJ, et al. Deep learning for prediction of obstructive disease from fast myocardial perfusion SPECT: a multicenter study. JACC Cardiovasc Imaging. 2018;11:1654–1663. DOI: 10.1016/j.jcmg.2018.01.020.

22. Haneuse S, VanderWeele TJ, Arterburn D. Using the e-value to assess the potential effect of unmeasured confounding in observational studies. JAMA. 2019;321:602–603.DOI: 10.1001/jama.2018.21554.

23. Alexopoulos N, McLean DS, Janik M, Arepalli CD, Stillman AE, Raggi P. Epicardial adipose tissue and coronary artery plaque characteristics. Atherosclerosis. 2010;210:150–154.DOI: 10.1016/j.atherosclerosis.2009.11.020.

24. Jang HC, Lee HK, Lee H, Cha JG, Kim YS, Cho JH. Analyzing correlation between epicardial fat area and metabolic syndrome risk factor by using low-dose lung CT. Pak J Med Sci. 2015;31:1207–1212.DOI: 10.12669/pjms.315.7991.

25. Kim MK, Tomita T, Kim MJ, Sasai H, Maeda S, Tanaka K. Aerobic exercise training reduces epicardial fat in obese men. J Appl Physiol. 1985;59:5–11.

26. Sinha SK, Thakur R, Jha MJ, Goel A, Kumar V, Kumar A, Mishra V, Varma CM, Krishna V, Singh AK, et al. Epicardial adipose tissue thickness and its association with the presence and severity of coronary artery disease in clinical setting: a cross-sectional observational study. J Clin Med Res. 2016;8:410–419. DOI: 10.14740/jocmr2468w.

27. Abbbara S, Desai JC, Cry RG, Butler J, Nieman K, Reddy V. Mapping epicardial fat with multi-detector computed tomography to facilitate percutaneous transepicardial arrhythmia ablation. Eur J Radiol. 2008;67:417–422. DOI: 10.1016/j.ejrad.2005.12.030.

28. Rajani R, Shmilovich H, Nakazato R, Nakashishi R, Dey D. Relationship of epicardial fat volume to coronary plaque, severe coronary stenosis, and high-risk coronary plaque features assessed by coronary CT angiography. J Cardiovasc Comput Tomogr. 2013;7:125–132. DOI: 10.1016/j.jcct.2013.02.003.

29. Ej Khoudary SR, Zhao Q, Venugopal V, Manson JE, Brooks MM, Santoro N, Black DM, Harman SM, Cedars MI, Hopkins PN, et al. Effects of hormone therapy on heart fat and coronary artery calcification progression: secondary analysis from the keeps trial. J Am Heart Assoc. 2019;8:e012763. DOI: 10.1161/JAHA.119.012763.

30. Cheng VY, Dey D, Tamarappoo B, Nakazato R, Grannar H, Miranda-Peats R, Ramesh A, Wong ND, Shaw LJ, Stomka PJ, et al. Pericardial fat burden on ECG-gated noncontrast CT in asymptomatic patients who subsequently experience adverse cardiovascular events. JACC Cardiovasc Imaging. 2010;3:352–360. DOI: 10.1016/j.jcmg.2009.12.013.